Hims & Hers Health, Inc. Class A Common Stock (HIMS)
51.08
+3.19 (6.66%)
NYSE · Last Trade: Jul 14th, 3:18 PM EDT
Detailed Quote
Previous Close
47.89
Open
47.82
Bid
51.05
Ask
51.08
Day's Range
47.36 - 51.76
52 Week Range
13.47 - 72.98
Volume
26,294,314
Market Cap
9.80B
PE Ratio (TTM)
75.12
EPS (TTM)
0.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
46,851,362
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
NEW YORK - July 14, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers (HIMS), Sarepta (SRPT), or PetCo (WOOF) To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Hims To Contact Him Directly To Discuss Their Options
NEW YORK - July 11, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit.
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) securities during the period of April 29, 2025, through June 23, 2025, inclusive (“the Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
RADNOR, PA - July 10, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( www.ktmc.com ) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. (“Hims & Hers”) ( NYSE: HIMS ) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is August 25, 2025.
NEW YORK - July 10, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit.
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
NEW ORLEANS, July 09, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 25, 2025 to file lead plaintiff applications in securities class action lawsuits against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased the Company’s securities between April 29, 2025 and June 23, 2025, inclusive (the “Class Period”). These actions are pending in the United States District Court for the Northern District of California.
PALM BEACH, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global telehealth market has been substantially growing over the past years and is expected to continue this growth well into the future. A report from Grand View Research said that: “The global telehealth market size was estimated at USD 123.26 billion in 2024 and is projected to reach USD 455.27 billion by 2030, growing at a CAGR of 24.68% from 2025 to 2030. North America dominated the telehealth market with the revenue share of 46.58% in 2024. The market is primarily driven by the increasing adoption of digital health & smartphones, rising investments, improved internet connectivity, and growing technological advancements… the growing adoption and acceptance of telehealth services are expected to boost the market's growth over the forecast period.” The report continued: “Moreover, smartphones have evolved from devices of communication & entertainment to devices that can monitor health and fitness. Some market players are developing Chatbot services for basic medical inquiries and one-time consultations… Moreover, the market is propelled by favorable government initiatives to expand telehealth by making healthcare services more accessible and convenient for patients. The focus on cost-effective and efficient healthcare solutions further propels the adoption of telehealth services. The rising adoption of telehealth facilities by patients, physicians, and government authorities is boosting the market. Access to healthcare through specific applications and video consultations enables communication between patients and doctors in remote locations, eliminating the need to visit hospitals or clinics. Market players such as Apple, Google, and IBM focus on improving the mobile health experience by providing numerous solutions through different subscription plans and emphasizing data security. These factors are expected to drive the market growth over the forecast period.” Active tech companies in the markets this week include Treatment AI, Inc. (OTCQB: TREIF) (CSE: TRUE), CVS Health® (NYSE: CVS), Teladoc Health, Inc. (NYSE: TDOC), Tempus AI, Inc. (NASDAQ: TEM), Hims & Hers Health, Inc. (NYSE: HIMS).
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 4.1% in the morning session after the company announced plans to expand into Canada with a weight-loss solution centered on generic semaglutide. The telehealth company intends to launch its weight loss program in Canada in 2026, a move timed to coincide with the expected global debut of a generic version of semaglutide. Semaglutide is the active ingredient in popular and effective, but costly, branded weight-loss drugs like Ozempic and Wegovy. Hims & Hers aims to capture a significant portion of the Canadian market, where the company notes that about two-thirds of adults are overweight or obese.
Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.
NEW YORK - July 9, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Hims & Hers Health, Inc. ("Hims & Hers Health, Inc." or the "Company") (NYSE: HIMS) of a class action securities lawsuit.
